{
    "clinical_study": {
        "@rank": "161565", 
        "arm_group": {
            "arm_group_label": "Candesartan cilexetil/amlodipine", 
            "description": "8 mg/2.5 mg or 8 mg/5 mg, orally, once daily"
        }, 
        "brief_summary": {
            "textblock": "This study will investigate the safety and efficacy of long-term use of candesartan\n      cilexetil/amlodipine combination tablets (Unisia Combination Tablets) LD, HD in patients\n      with hypertension in the normal clinical setting."
        }, 
        "brief_title": "Candesartan Cilexetil/Amlodipine Combination Tablets LD, HD Special Drug Use Surveillance \"Hypertension: Long-Term Use\"", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This special drug use surveillance was designed to investigate the safety and efficacy of\n      long-term use of candesartan cilexetil/amlodipine combination tablets (Unisia Combination\n      Tablets) in patients with hypertension in the routine clinical setting.\n\n      The usual adult dosage is one tablet (8 mg/2.5 mg or 8 mg/5 mg as candesartan\n      cilexetil/amlodipine) administered orally once daily."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with hypertension\n\n        Exclusion Criteria:\n\n          -  Patients in whom Unisia is contraindicated [Contraindications]\n\n               1. Patients with a history of hypersensitivity to the ingredients of Unisia or any\n                  other dihydropyridine formulations\n\n               2. Women who are pregnant or of child-bearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hypertension"
            }
        }, 
        "enrollment": {
            "#text": "3409", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068495", 
            "org_study_id": "119-011", 
            "secondary_id": "JapicCTI-132390"
        }, 
        "intervention": {
            "arm_group_label": "Candesartan cilexetil/amlodipine", 
            "description": "Candesartan cilexetil/amlodipine tablets", 
            "intervention_name": "Candesartan cilexetil/amlodipine", 
            "intervention_type": "Drug", 
            "other_name": "Unisia Combination Tablets"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Candesartan cilexetil", 
                "Candesartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "February 19, 2014", 
        "number_of_groups": "1", 
        "official_title": "Unisia Combination Tablets LD, HD Special Drug Use Surveillance \"Hypertension: Long-Term Use\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Frequency, severity, and time to onset of adverse events and adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..", 
            "measure": "Frequency of adverse events and adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "12 months from the baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068495"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculation of summary statistics for actual measurement values and the  change from baseline in systolic and diastolic blood pressure.", 
            "measure": "Changes in blood pressure, achievement rate of the target blood pressure levels", 
            "safety_issue": "No", 
            "time_frame": "12 months from baseline"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}